BioSpace News Archive

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present at th

Global safety equipment manufacturer MSA Safety Incorporated (NYSE: MSA) today announced that its next-generation Advantage 290 LS Air-Purifying Respirator (APR) is the first of its kind — designed without an exhalation valve — to receive approval from the National Institute for Occupational Safety and Health (NIOSH).

The Canadian Partnership Against Cancer is working with partners across Canada to innovate cancer care, with a focus on improving access to world class cancer screening services for underserviced populations in the wake of a pandemic that’s changed the face of health care TORONTO , Nov. 25, 2020 /CNW/ - The Canadian Partnership Against Cancer (the Partnership) is i

ESSA Pharma Inc. (Nasdaq: EPIX) , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3 rd Annual HealthCONx Conference.

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, granted a stock option to a new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan

LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that members of the executive management team will participate in a virtual fireside chat at the 3 rd Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 3 at 1:50 p.m. ET. A live webcast of the presentation will be available via the company website at www.LabC

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the publication of the largest case series using CytoSorb in critically ill

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approxim

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced top-line results from its 755-101-HV Phase 1 clinical trial (“Study 101").

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce the completion of its rights offering (the “Rights Offering”), which expired at 5:00 pm (EST) on November 24, 2020.